Madeleine Johnson

The firm has multiple infectious disease tests in its pipeline and is currently in initial conversations with potential investors and partners.

The technology may enable better adherence to clinical guidelines on the frontlines of healthcare.

Published on Monday, the work describes a foundational technology being commercialized by startup VedaBio.

Will the acquisition finally lead to an accelerated adoption of digital PCR in the clinical space?

Core revenues for full-year 2024 grew 7 percent to $281.2 million.

Researchers at New York University expect to launch a clinical trial in the near future following a successful validation of their approach.

Bio-Rad plans to drive adoption of Stilla's all-in-one Nio+ dPCR system while also incorporating its own assays to expand the menu.

Researchers have begun validating the new method that can reduce lab contamination and obviate the need for lyophilization.

The pneumonia test will detect pathogen RNA in blood samples using Qiagen's newly launched clinical system.

The separation is planned to be completed by the end of 2026 with the rest of the company transforming into a pure play medical technology firm.